Pharmacological blockade of a β₂AR-β-arrestin-1 signaling cascade prevents the accumulation of DNA damage in a behavioral stress model

Abstract

Chronic stress is known to have a profound negative impact on human health and has been suggested to influence a number of disease states. However, the mechanisms underlying the deleterious effects of stress remain largely unknown. Stress is known to promote the release of epinephrine, a catecholamine stress hormone that binds to β₂-adrenergic receptors (β₂ARs) with high affinity. Our previous work has demonstrated that chronic stimulation of a β₂AR-β-arrestin-1-mediated signaling pathway by infusion of isoproterenol suppresses p53 levels and impairs genomic integrity. In this pathway, β-arrestin-1, which is activated via β₂ARs, facilitates the AKT-mediated activation of Mdm2 and functions as a molecular scaffold to promote the binding and degradation of p53 by the E3-ubiquitin ligase, Mdm2. Here, we show that chronic restraint stress in mice recapitulates the effects of isoproterenol infusion to reduce p53 levels and results in the accumulation of DNA damage in the frontal cortex of the brain, two effects that are abrogated by the β-blocker, propranolol and by genetic deletion of β-arrestin-1. These data suggest that the β₂AR-β-arrestin-1 signaling pathway may represent an attractive therapeutic target to prevent some of the negative consequences of stress in the treatment of stress-related disorders.

Keywords: :

• DNA damage
• adrenergic receptor
• arrestin
• stress
• β-blocker

Stress Response Pathways

More than 70 y ago, Hans Selye¹ first recognized a clinical constellation of “nonspecific disease features” that occur in response to acute or chronic stress and referred to these collectively as “the stress response.” The stress response is mediated primarily by two systems: the hypothalamic-pituitary-adrenocortical (HPA) axis and the autonomic nervous system (ANS). Secreted hormones from these systems (corticosteroids and catecholamines, respectively) can affect every system of the body that expresses the relevant receptors. The stress response in the ANS is primarily mediated by stimulation of the sympathetic nervous system (SNS) and the subsequent release of the catecholamine hormone, epinephrine and the neurotransmitter, norepinephrine. Epinephrine binds to the β₂-subtype of adrenergic receptors (β₂ARs) with high affinity.

The catabolic, lipogenic, anti-reproductive and immunosuppressive effects of HPA axis activation allow an organism to resist and recover from stress and challenges to homeostasis. SNS activation and secretion of epinephrine facilitate the “fight-or-flight” response. However, the stress response in humans also engenders unwanted effects.² Because of the nature of chronic psychosocial stress, aspects of the stress response may continue for an extended period, leading to prolonged secretion of stress hormones and consequent potentially undesirable effects to affected individuals. Although chronic stress represents a major risk factor for a number of human diseases [e.g., Alzheimer disease,³ type 2 diabetes,⁴ cardiovascular disease,⁵ cancer⁶ and post-traumatic stress disorder (PTSD)^7,8], its clinical importance remains controversial due, at least in part, to difficulties associated with conducting standardized human behavioral studies.

Accumulation of DNA Damage via β₂AR-Mediated Stress Response Pathways

β₂ARs are prototypical G-protein-coupled receptors (GPCRs)^9-11 that are identified throughout the body, including in the brain, lung, skeletal muscle and bone marrow.^12,13 The β₂ARs regulate numerous physiological processes, such as glycogenolysis in the liver¹⁴ or relaxation of vascular smooth muscle.¹⁵ Stimulation of the β₂AR leads to Gs-dependent adenylyl cyclase activation and cAMP production, followed by the activation of protein kinase A (PKA).^11,16 Desensitization of the β₂AR is conferred by G-protein-coupled receptor kinase (GRK)-dependent phosphorylation,¹⁷ followed by the recruitment of β-arrestins,¹⁸ which are known to function as independent signal transducers in addition to their roles in receptor desensitization.^19,20 The E3-ubiquitin ligase Mdm2 catalyzes the transient ubiquitination of β-arrestins, which is required for clathrin-mediated β₂AR internalization.²¹

Recently, we elucidated a novel molecular mechanism by which chronic stimulation of β₂AR activates Gs-PKA and β-arrestin-1-mediated signaling pathways, which trigger DNA damage and degrade p53, respectively. The activation of these two pathways synergistically leads to accumulation of DNA damage (Fig. 1).²² Stimulation of the β₂AR leads to β-arrestin-1-mediated activation of AKT and phosphorylation of Mdm2 at Ser 166, which results in the activation of Mdm2. Mdm2 activation then leads to β-arrestin-1-facilitated ubiquitination and degradation of p53, during which β-arrestin-1 acts as an E3-ubiquitin ligase adaptor. Meanwhile, stimulation of β₂AR leads to the production of reactive oxygen species by NAD(P)H oxidase,²³ activation of adenylyl cyclase and PKA signaling (the downstream targets of the β₂AR-G-protein signaling cascade) and the promotion of oxidative stress via the suppression of antioxidative mechanisms.²⁴ Thus, upon chronic secretion of catecholamines and stimulation of β₂ARs, G-protein and β-arrestin cascades lead to increased oxidative stress and decreased p53 levels, respectively, thus lowering genome maintenance and increasing DNA damage and de novo genomic rearrangements.²² β-arrestin-1 plays a dual role in this process. First, cytosolic β-arrestin-1 mediates the activation of PI3K/AKT upon β₂AR stimulation. Second, nuclear β-arrestin-1 scaffolds Mdm2 to p53, facilitating the ubiquitination and degradation of p53.

Figure 1. Schematic diagram of β₂AR-dependent regulation of DNA damage in the catecholamine-mediated stress response. The stress response and activation of the sympathetic nervous system (SNS) release catecholamine stress hormones, such as epinephrine, which activate β₂AR and its downstream signaling pathways. This initiates activation of Gs-PKA signaling and cytosolic β-arrestin-1 (βArr1: orange)-mediated activation of PI3K/AKT signaling leading to phosphorylation and activation of Mdm2. βArr1 in the nucleus (white) facilitates the Mdm2-mediated nuclear export and degradation of p53, compromising genome maintenance.²² Meanwhile, stimulation of β₂AR leads to production of reactive oxygen species by NAD(P)H oxidase,²³ and activation of adenylyl cyclase and PKA signaling promotes oxidative stress by suppressing antioxidative mechanisms.²⁴ Thus, these two independent G-protein and β-arrestin-mediated pathways synergistically affect the accumulation of DNA damage. P, phosphorylation at ser 166 on Mdm2; U, ubiquitination.

A Behavioral Stress Model Leads to a β₂AR-β-Arrestin-1 Signaling Cascade-Mediated Accumulation of DNA Damage

In our previous study, chronic administration of catecholamines was used to mimic the conditions under which stress leads to the stimulation of β₂ARs.²² To examine β₂AR-β-arrestin-1 signaling cascades under more physiological conditions, we utilized a chronic restraint stress model, which has been shown to promote secretion of epinephrine and norepinephrine.²⁵ After 2 wk of restraint stress, we observe an accumulation of DNA damage and reduced levels of p53 in the brain frontal cortex (Fig. 2A), which is a site particularly susceptible to chronic stress.²⁶ These responses are mediated through a β₂AR-β-arrestin-1 signaling cascade, because genetic deletion of β-arrestin-1 abrogates these effects (Fig. 2B). Furthermore, administering propranolol, a blood-brain-barrier permeant β-blocker,²⁷ also prevents these effects, indicating that βARs stimulated by endogenous β-adrenergic catecholamines are responsible (Fig. 2C).

Figure 2. Behavioral stress leads to accumulation of DNA damage and reduced levels of p53. (A) Restraint stress leads to accumulation of DNA damage and lowering levels of p53. After restraint stress, wild-type mice (WT) were sacrificed, brains were removed, and brain frontal cortex was dissected. Their homogenates were analyzed by immunoblotting with indicated antibodies. DNA damage was examined by phosphorylation of histone H2AX (γ-H2AX), one of the earliest indicators of DNA damage.⁶³ Mean ± SEM. Student’s t-test, two-tailed. n = 10 for each condition. (B) Genetic deletion of β-arrestin-1 abrogates the DNA damage accumulation and p53 degradation induced by restraint stress. After restraint stress, β-arrestin-1-knockout mice (βArr1^−/−) were sacrificed, brains were removed, and brain frontal cortex was dissected. Mean ± SEM. Student’s t-test, two-tailed. n = 5 for each condition. (C) Propranolol, a β-blocker, inhibits the accumulation of DNA damage and p53 degradation induced by restraint stress. Propranolol (Prop) was administered to WT, starting 2 d before the first exposure to restraint stress. Mean ± SEM. Student’s t-test, two-tailed. n = 10 for each condition.

Recently, Feng et al.²⁸ reported that chronic restraint stress decreases p53 protein levels and promotes tumorigenesis in mice exposed to ionizing radiation (IR). Interestingly, the authors found that the HPA axis-dependent glucocorticoids induce activation of SGK1 (serum- and glucocorticoid-induced protein kinase 1), followed by phosphorylation of Mdm2 at Ser 166, which facilitates p53 degradation. Because β-adrenergic catecholamines also lead to phosphorylation of Mdm2 at Ser 166,²² both the SNS and the HPA axis, with β-adrenergic catecholamines and glucocorticoids, respectively, may synergistically affect Mdm2 function, thus lowering p53 levels.²⁹

β-Blockers

β-blockers, which are antagonists of β₁- and/or β₂-adrenergic receptors, are widely prescribed therapeutic agents for the chronic treatment of heart failure, in which they act via poorly understood mechanisms to afford cardioprotection.³⁰ Interestingly, clinical and epidemiological studies suggest that β-blockers have additional therapeutic benefits. For example, chronic β-blocker therapy is associated with lower incidences of prostate cancer³¹ and reduced metastasis, tumor recurrence and specific mortality in breast cancer.³² Treatment with the β-blocker propranolol has been recently used as an effective therapy for an infantile vascular tumor, hemangiomas, causing regression.³³ Behavioral stress in mice increases ovarian tumor growth, and this effect is inhibited by administering the β-blocker propranolol or RNA interference (RNAi) against β₂AR.³⁴ In a mouse stroke model for middle cerebral artery occlusion (MCAO), administering the β₂AR-selective β-blocker ICI 118,551 or genetic deletion of β₂AR decrease post-ischemic brain injury.³⁵ In psychiatric disorders, treatment with the β-blocker propranolol decreases PTSD after trauma⁸ and anxiety-like behavior by repeated social defeat.⁷ These studies implicate diverse effects of β-blockers that potentially involve inhibition of either or both G-protein and β-arrestin signaling cascades.

The data we present here demonstrate that administering the non-subtype selective β-blocker propranolol prevents behavioral stress-induced accumulation of DNA damage and degradation of p53 (Fig. 2C). These effects are, at least in part, mediated through inhibition of a β₂AR-β-arrestin-1 signaling cascade, because genetic deletion of β-arresin-1 shows effects similar to β-blockade (Fig. 2B). β-blockers have been developed as antagonists for βARs, mainly targeting G-protein signaling. Our data highlight the therapeutic potential of β-blockers, also targeting effects of β-arrestin-1 signaling that affects p53 levels and genome integrity during chronic stress.

β-Arrestin-1, p53 and Mdm2

The role of β-arrestin-1 as a negative regulator of p53^22,36 is in contrast to a previously reported role for β-arrestin-2, which has been shown to anchor Mdm2 in the cytosol and thereby stabilize nuclear p53.^37,38 These strikingly different results may simply reflect the distinct cellular localization of these isoforms (β-arrestin-2 is confined to the cytosol). The fact that the addition of a nuclear export signal to β-arrestin-1 abolished its effect on p53²² strongly supports this interpretation. Alternatively, these differences may be indicative of a very specific, and yet to be fully appreciated, role for the different β-arrestin isoforms downstream of specific receptors in different physiologically relevant pathways.^39,40 Furthermore, the identification of β-arrestin-1 as an E3-ubiquitin ligase adaptor in the nucleus, adds to the growing list of nuclear roles of β-arrestin-1.⁴¹ It has been shown that nuclear β-arrestin-1 regulates transcription of p27, c-fos and Bcl-2 by scaffolding the transcription factor CREB (cAMP response element-binding) and the acetyl transferase p300, which acetylates histone H4 and activates gene expression.^42,43 β-arrestin-1 also sequesters the polycomb group (PcG) recruiter YY1, relieving PcG-mediated gene repression.⁴⁴

p53, the “guardian of the genome,”⁴⁵ regulates cell cycle arrest, DNA repair and/or apoptosis incurred under both basal and genotoxic conditions via transcription-dependent and -independent mechanisms.⁴⁶ Although we have investigated a role of p53 in genome maintenance, it is conceivable that other aspects of p53 function are also affected by the prolonged decreases in p53 levels caused by catecholamines. These include, but are not limited to, the induction of cell death by PUMA (p53-upregulated modulator of apoptosis),^47,48 the regulation of metabolic pathways by TIGAR (TP53-induced glycolysis and apoptosis regulator)⁴⁹ and SCO2 (synthesis of cytochrome c oxidase 2),⁵⁰ centrosome duplication⁵¹ and the regulation of maternal reproduction through LIF (leukemia-inhibitory factor).⁵² Furthermore, p63, a p53 homolog, has been shown to protect the female germ line during meiotic arrest.⁵³ It remains to be determined whether catecholamine hormones affect the stability of p53 homologs.

Mdm2 is one of the most well-established regulators of p53.⁵⁴ The catalytic activity of Mdm2 is regulated by a variety of interacting molecules, such as the acetyl transferase, p300,⁵⁵ or the tumor suppressor, ARF.^56,57 In our previous study,²² we showed that with chronic administration of catecholamines to mimic stress-induced β₂AR-stimulated conditions, β-arrestin-1 plays a key role in the Mdm2-p53 cascade, facilitating the binding of Mdm2 and p53 in the nucleus and the resulting degradation of p53. This is reminiscent of the role of β-arrestins in the cytosol, where they serve as adaptors for Mdm2-dependent ubiquitination and degradation of its substrates.^58-60 In addition, recent studies have shown that β-arrestins and related molecules serve as adaptors for other E3-ubiquitin ligases.⁶¹ These studies indicate that β-arrestins may have a general role as scaffolding molecules in diverse ubiquitination pathways.

Conclusions

Our results provide a plausible explanation of the mechanism through which chronic stress and prolonged activation of the SNS can influence genomic integrity. Catecholamine hormones secreted during chronic stress activate β₂ARs and trigger both G-protein and β-arrestin-1 signaling cascades. The former influences oxidative stress,^23,24 and the latter influences genome maintenance by regulating p53.^22,36 The demonstration of the effects of stress hormones on DNA damage represents a conceptual as well as a tangible advance. Such a process could not only explain the development of some human disorders and conditions, such as aging or cancer, but also suggests a model supporting potential prophylactic and/or therapeutic interventions. Consistent with this hypothesis, our current study showed that the β-blocker propranolol inhibited DNA damage accumulation in response to stress. Considering the pleiotropic effects of β₂ARs, selectively targeting β-arrestin-1, one of its signaling arms, could represent an attractive therapeutic approach to prevent/block/ameliorate the negative consequences of stress.

In addition to the therapeutic relevance of our findings, the evidence that the accumulation of DNA damage induced by behavioral stress involves the β₂AR-β-arrestin-1 system provides support for the concept that the β-arrestin-1 signaling cascade may play an important role in helping to maintain the integrity of the genome.

Materials and Methods

Reagents

Propranolol was purchased from Sigma. Antibodies were obtained from the following companies: anti-γ-H2AX monoclonal antibody was from Molecular Probes, anti-tubulin antibody from Sigma, anti-p53 (FL-393) antibody was from Santa Cruz.

Restraint stress

WT (C57BL/6) or βArr1-knockout (βArr1^−/−)⁶² mice were restrained in 50-ml conical tubes, which were uniformly perforated for ventilation, for 4 h/d for 2 wk. Propranolol (10 mg/kg/day) was administered in the drinking water and was kept in a light-protected bottle, starting 2 d before the first exposure to restraint stress. After restraint stress, animals were sacrificed, brains were removed, and brain frontal cortex was dissected. For protein preparation, the brain frontal cortex was lysed and sonicated in RIPA buffer (50 mM Tris pH 7.4, 500 mM NaCl, 1% SDS, 1% Triton X100, 1 mM EDTA, Halt protease and phosphatase inhibitor cocktail). All animals used in these studies were adult male mice 8–12 wk of age. All mouse strains were backcrossed to the C57BL/6 background ≥ 10 generations. Animals were handled according to approved protocols and animal welfare regulations of the Institutional Review Board at Duke University Medical Center.

Immunoblotting

Immunoblotting was performed as described in reference 22.

Acknowledgments

R.J.L. is a Howard Hughes Medical Institute investigator. This work was supported by HL16037 and HL70631 (R.J.L.), RO1-MH79201 and RO1-MH60451 (M.G.C) and F32- MH093092 (B.D.S). We thank D. Addison and Q. Lennon for secretarial assistance.